Drugs / IA-14069
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05533372 | Oct 2022 → Nov 2025 overdue | rheumatoid arthritis | ILAb Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05317741 | Aug 2021 → Sep 2022 | — | ILAb Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IA-14069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05317741 ↗ |
| Route | Oral | “Subjects received IA-14069 tablet orally on Day 1.” NCT05317741 ↗ |